Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The prognostic value of FLT3-ITD residual disease in AML

Peter Valk • 29 Sep 2022
SOHO 2022
Acute Myeloid Leukemia Leukemia

Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the prognostic value of FLT3-ITD residual disease in patients with acute myeloid leukemia (AML). Dr Valk highlights the results of a study which used next-generation sequencing (NGS) to evaluate the impact of FLT3-ITD on the risk of relapse in patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter Valk

1:03
Future considerations for MRD in AML
Peter Valk • 29 Sep 2022
2:20
Distinguishing between de novo AML and secondary AML using mutational signatures
Peter Valk • 29 Sep 2022
3:22
Is TP53-mutated high-risk MDS the same disease as TP53-mutated AML?
Peter Valk • 29 Sep 2022
2:44
Ongoing and future AML research at the Valk Lab
Peter Valk • 1 Apr 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals